Article

Smoking Doubles Recurrent Tuberculosis Risk

Author(s):

Smoking tobacco doubles a patient's risk of developing recurrent tuberculosis (TB), according to a study published in the April issue of the International Journal of Tuberculosis and Lung Disease.

Smoking tobacco doubles a patient’s risk of developing recurrent tuberculosis (TB), according to a study published in the April 2014 issue of the International Journal of Tuberculosis and Lung Disease.

For the study, researchers from the National Yang-Ming University sampled 5,567 Taiwanese adults with a mean age of 58.5 years and bacteriologically confirmed TB. Of those patients, 1.5% developed TB after being successfully treated for the infectious disease in the past. Regular tobacco smokers, who were defined as individuals who smoked more than 10 cigarettes per day, were twice as likely to develop recurrent TB compared to former smokers and individuals who had never smoked.

“Unless we adapt our TB control strategies to respond to newly ascertained risks — such as smoking tobacco, the global rise in diabetes, and the overcrowding we see in cities as the world urbanizes — we will always remain 2 steps behind the bacteria,” Luis Castro, Interim Executive Director of The International Union Against TB and Lung Disease, said in a statement.

The researchers noted that other independent risk factors associated with TB recurrence included homelessness, presence of comorbidities, and a positive acid-fast bacilli smear. Current TB treatment options require a patient to take several drugs for a minimum of 6 months, but among some especially drug-resistant cases, that period can last up to 2 years or more.

“No one should undergo the long, complex treatment for TB only to unknowingly place themselves at heightened risk of getting the disease again,” the authors wrote. “With this research, we can inform national tobacco control policies and educate patients about the risks that smoking tobacco poses.”

The authors also recommended introducing effective smoking cessation measures in TB control programs that align with the World Health Organization (WHO) Stop TB Strategy.

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
© 2024 MJH Life Sciences

All rights reserved.